Bitcoin's price fell below its 50-day moving average for the first time in 66 days, closing at $80,806, about 1.23% below the $81,807 average. This break is significant mainly for short-term trading algorithms rather than indicating a long-term trend change, as the price remains well above the 200-day average by 10.84%. The recent price dip was influenced by $635 million in outflows from US spot ETFs and a pullback in tech stocks, causing selling pressure outside the crypto market. Meanwhile, Bitcoin's mining difficulty is set to rise by an estimated 5.55% on October 29, increasing mining costs amid sideways price movement. Investors should watch key resistance levels at $81,807 and $82,560 and support at $80,455 and $75,291 for near-term price action.
Bitcoin's price fell below its 50-day moving average for the first time in 66 days. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 24, 2026 13:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell today. Notable movers include ATOM at Rp30.176 with a 1-day change of -6.08% and a Pluang order activity of 54% Sell / 46% Buy, LTC at Rp1.028.835 with a 1-day change of -4.45% and 78% Sell / 22% Buy, and AAVE at Rp2.581.330 with a 1-day change of -4.25% and 31% Sell / 69% Buy. Typical hold times on Pluang range from 61 to 106 days among these assets.
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
Zymeworks presented new Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing a 64.5% confirmed response rate at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The treat...
